太龙药业：收到反垄断审查不实施进一步审查决定书，控股股东及实控人拟变更

Core Viewpoint - The company has received a decision from the National Market Supervision Administration indicating that no further antitrust review will be conducted on Jiangyao Group's acquisition of shares in Tailong Pharmaceutical, allowing the acquisition to proceed [1] Group 1: Acquisition Details - Jiangyao Group will acquire 50,100,000 shares of Tailong Pharmaceutical, representing 8.73% of the total share capital, at a price of 11.043 yuan per share, totaling 553,254,300 yuan [1] - Following the completion of the first share transfer and the effectiveness of the action agreement, Jiangyao Group will hold 42,300,000 shares, which is 7.37% of the total share capital, and will control a total of 14.37% of the company through the agreement [1] Group 2: Changes in Control - The controlling shareholder will change from Tai Rong Investment to Jiangyao Group, and the actual controller will shift from the Zhengzhou High-tech Industrial Development Zone Management Committee to the Jiangxi Provincial State-owned Assets Supervision and Administration Commission [1]